Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqitongluo granule
- Development stage
- Phase 4
- Lead developer
- China Shineway Pharmaceutical Group
- Administration
- Oral
01
Overview
Yiqitongluo granule (YQTL) is a traditional Chinese medicine (TCM) formulation developed as a botanical drug for cerebrovascular diseases. It is manufactured by China Shineway Pharmaceutical Group Ltd. [13]. YQTL is a complex herbal mixture that has shown therapeutic effects against cerebral ischemia/reperfusion injury (CIRI) and ischemic stroke in preclinical and clinical studies. Research indicates that its neuroprotective effects are mediated through multiple pathways, including the inhibition of nerve cell apoptosis by enhancing the PI3K-Akt signaling pathway and modulating the NMDAR/ERK1/2 signaling pathway. [13, 17] Clinical trials are evaluating its efficacy in conditions associated with qi deficiency and blood stasis, such as the convalescence of ischemic stroke, stable coronary artery disease, and diabetic peripheral neuropathy.
- Brand names
- yiqi tongluo granuleyiqi tongluo capsule
- Other names
- Yiqi Tongluo GranuleYi-Qi-Tong-Luo granule益气通络颗粒
02
Targets
CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)
Beyond the preview
Go deeper on Yiqitongluo granule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yiqitongluo granule.